Mahendra Gunapooti, MD
Interventional Pain Medicine · Florissant, MONPI 1114034931
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 160 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 30 manufacturers reported payments, led by Salix Pharmaceuticals, A Division Of Bausch Health US, LLC at 26.7% of the total. That places this record below the midpoint for interventional pain medicine clinicians in MO, where the typical reported total is $2,673.
Across 160 payments — averaging $16.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$713
- AbbVie$328
- Pfizer$245
- Protega Pharmaceutials Inc$186
- Biohaven Pharmaceutical Holding Company Ltd.$181
- Amgen$138
- plus $881 from 24 others
What the payments were for
- Food & beverage$2,673100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 60 | $713 |
| AbbVie | 20 | $328 |
| Pfizer | 16 | $245 |
| Protega Pharmaceutials Inc | 5 | $186 |
| Biohaven Pharmaceutical Holding Company Ltd. | 5 | $181 |
| Amgen(2 entities) | 7 | $138 |
| Axsome Therapeutics, Inc. | 3 | $125 |
| Valinor Pharma, LLC | 5 | $88 |
| Biohaven Pharmaceuticals, Inc. | 4 | $73 |
| GRT US Holding, Inc. | 3 | $68 |
| Biodelivery Sciences International, Inc. | 4 | $62 |
| Scilex Pharmaceuticals Inc. | 3 | $56 |
| AstraZeneca | 4 | $48 |
| Novartis | 2 | $39 |
| IBSA Pharma Inc. | 2 | $32 |
| Arbor Pharmaceuticals, Inc. | 2 | $32 |
| Esaote North America, Inc. | 1 | $31 |
| Fidia Pharma USA Inc. | 2 | $27 |
| Forte Bio-pharma LLC | 1 | $25 |
| Abbott | 1 | $23 |
| Boston Scientific | 1 | $20 |
| SPR Therapeutics, Inc | 1 | $20 |
| Tonix Medicines, Inc. | 1 | $18 |
| G Medical Diagnostic Services, Inc. | 1 | $17 |
| Lilly USA, LLC | 1 | $15 |
| Arteriocyte Medical Systems, Inc. | 1 | $15 |
| Collegium Pharmaceutical, Inc. | 1 | $14 |
| Virtus Pharmaceuticals LLC | 1 | $13 |
| Shionogi Inc | 1 | $11 |
| Assertio Therapeutics, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NURTEC ODT$116
How this compares
$2,673 in reported general payments places this provider in the 50th percentile of 27 interventional pain medicine providers in Missouri.
See all interventional pain medicine providers in Missouri →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RelistorMethylnaltrexone Bromide | 233 | $550,849 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 3,468 | $79,190 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 2,973 | $64,230 |
| MovantikNaloxegol Oxalate | 125 | $54,990 |
| Nurtec OdtRimegepant Sulfate | 25 | $34,921 |
| Acetaminophen-CodeineAcetaminophen With Codeine | 1,894 | $23,045 |
| Lidocaine | 288 | $17,954 |
| OxycontinOxycodone Hcl | 27 | $16,831 |
| Fentanyl | 193 | $15,096 |
| Cyclobenzaprine Hcl | 1,281 | $13,052 |
| Gabapentin | 896 | $11,575 |
| Tramadol Hcl | 933 | $9,698 |
| Tizanidine Hcl | 469 | $8,678 |
| Morphine Sulfate ErMorphine Sulfate | 300 | $8,129 |
| Methocarbamol | 540 | $7,661 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCRelistor | $713 | $550,849233 claims |
| PfizerNurtec Odt | $245 | $34,92125 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 27 interventional pain medicine providers in Missouri.
Other interventional pain medicine in Florissant
- Rebecca SandersJoplin$209K
- Ramis GheithBridgeton$73K
- Helen BlakeChesterfield$48K
- Andrew FrazierKansas City$32K
- Christian OliverBridgeton$18K
- David TonkinSpringfield$14K
- Dwayne JonesKansas City$11K
- Bradford NobleColumbia$8K
- Calvin CajigalDes Peres$8K
- James NewtonColumbia$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.